Tesaro Inc (TSRO) 93.24 $TSRO
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
GlobeNewswire - Fri Jul 08, 3:05PM CDT
-- The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort
TSRO: 93.24 (-0.38)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
GlobeNewswire - Thu Jul 07, 3:05PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 5,347,500 shares of its common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pursuant to the full exercise of the underwriters' option. TESARO estimates that the net proceeds from the offering will be approximately $409.0 million, after deducting the underwriting discount and other offering expenses payable by TESARO. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities acted as bookrunners, and Guggenheim Securities, Mizuho Securities, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow acted as co-managers for the offering.
TSRO: 93.24 (-0.38)
TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
GlobeNewswire - Thu Jun 23, 5:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 to 25, 2016, in Adelaide, Australia.
TSRO: 93.24 (-0.38)
Noteworthy Thursday Option Activity: TSRO, MRVL, AKS
DividendChannel.com - Thu Jun 16, 2:35PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 2,802 contracts has been traded thus far today, a contract volume which is representative of...
TSRO: 93.24 (-0.38)
TESARO Provides Pipeline Update at ASCO Investor Briefing
GlobeNewswire - Sat Jun 04, 6:00PM CDT
-- Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017
TSRO: 93.24 (-0.38)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 57.18 (+1.09), SQNM: 2.36 (-0.01), TSRO: 93.24 (-0.38), NKTR: 17.29 (+1.19)
TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by the New England Venture Capital Association
GlobeNewswire - Thu May 19, 4:46PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards celebrate New England's Life Science and Tech communities.
TSRO: 93.24 (-0.38)
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.
TSRO: 93.24 (-0.38)
WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
PR Newswire - Tue May 10, 7:00AM CDT
WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TSRO: 93.24 (-0.38)
Tesaro reports 1Q loss
Automated Insights - Thu May 05, 6:21PM CDT
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a loss of $90.8 million in its first quarter.
TSRO: 93.24 (-0.38)
TESARO Announces First-Quarter 2016 Operating Results
GlobeNewswire - Thu May 05, 3:06PM CDT
-- U.S. launch of VARUBI(R) underway; New Drug Application (NDA) for IV formulation of rolapitant submitted
TSRO: 93.24 (-0.38)
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
GlobeNewswire - Mon Apr 25, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
TSRO: 93.24 (-0.38)
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 21, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI(R) launch.
TSRO: 93.24 (-0.38)
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen
GlobeNewswire - Wed Apr 06, 6:00AM CDT
-- Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan
TSRO: 93.24 (-0.38)
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
GlobeNewswire - Mon Apr 04, 7:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company's Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
TSRO: 93.24 (-0.38)
TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042
GlobeNewswire - Tue Mar 29, 7:08AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced it has dosed the first patient in a Phase 1, dose-escalation study of its lead anti-PD-1 monoclonal antibody candidate, TSR-042. Following identification of a dose and schedule for TSR-042, the trial is planned to expand into tumor specific cohorts.
TSRO: 93.24 (-0.38)
TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement
GlobeNewswire - Tue Mar 29, 7:08AM CDT
-- Goal to identify novel small molecule therapeutics against undisclosed immuno-oncology targets
TSRO: 93.24 (-0.38)
TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
GlobeNewswire - Wed Mar 23, 8:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for oral rolapitant has been submitted to and validated by the European Medicines Agency. Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist that is marketed by TESARO in the United States under the brand name VARUBI(R).
TSRO: 93.24 (-0.38)
Ally Bridge Group (ABG) Completes Its Investment in TESARO, Inc. (TSRO)
PR Newswire - Mon Mar 21, 10:25AM CDT
Ally Bridge Group ("ABG"
, a global healthcare-focused investment group, announced that it has completed an equity investment in TESARO, Inc. (NASDAQ:TSRO), an oncology-focused, commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, USA. This investment was made as part of a private placement of 4.4 million shares of TSRO common stock that closed on March 17, 2016, resulting in gross proceeds of $155 million.
TSRO: 93.24 (-0.38)
TESARO Announces Closing of $155 Million Private Placement
GlobeNewswire - Fri Mar 18, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 million shares of common stock at a price of $35.19 per share. This transaction resulted in total gross proceeds to the Company of approximately $155 million. TESARO intends to use the proceeds from the financing primarily to support the development of its product pipeline and for general corporate purposes.
TSRO: 93.24 (-0.38)
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
GlobeNewswire - Fri Jul 08, 3:05PM CDT
-- The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort
TSRO: 93.24 (-0.38)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
GlobeNewswire - Thu Jul 07, 3:05PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 5,347,500 shares of its common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pursuant to the full exercise of the underwriters' option. TESARO estimates that the net proceeds from the offering will be approximately $409.0 million, after deducting the underwriting discount and other offering expenses payable by TESARO. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities acted as bookrunners, and Guggenheim Securities, Mizuho Securities, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow acted as co-managers for the offering.
TSRO: 93.24 (-0.38)
TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
GlobeNewswire - Thu Jun 23, 5:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 to 25, 2016, in Adelaide, Australia.
TSRO: 93.24 (-0.38)
Noteworthy Thursday Option Activity: TSRO, MRVL, AKS
DividendChannel.com - Thu Jun 16, 2:35PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 2,802 contracts has been traded thus far today, a contract volume which is representative of...
TSRO: 93.24 (-0.38)
TESARO Provides Pipeline Update at ASCO Investor Briefing
GlobeNewswire - Sat Jun 04, 6:00PM CDT
-- Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017
TSRO: 93.24 (-0.38)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 57.18 (+1.09), SQNM: 2.36 (-0.01), TSRO: 93.24 (-0.38), NKTR: 17.29 (+1.19)
TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by the New England Venture Capital Association
GlobeNewswire - Thu May 19, 4:46PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards celebrate New England's Life Science and Tech communities.
TSRO: 93.24 (-0.38)
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.
TSRO: 93.24 (-0.38)
WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
PR Newswire - Tue May 10, 7:00AM CDT
WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TSRO: 93.24 (-0.38)
Tesaro reports 1Q loss
Automated Insights - Thu May 05, 6:21PM CDT
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a loss of $90.8 million in its first quarter.
TSRO: 93.24 (-0.38)
TESARO Announces First-Quarter 2016 Operating Results
GlobeNewswire - Thu May 05, 3:06PM CDT
-- U.S. launch of VARUBI(R) underway; New Drug Application (NDA) for IV formulation of rolapitant submitted
TSRO: 93.24 (-0.38)
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
GlobeNewswire - Mon Apr 25, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
TSRO: 93.24 (-0.38)
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 21, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI(R) launch.
TSRO: 93.24 (-0.38)
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen
GlobeNewswire - Wed Apr 06, 6:00AM CDT
-- Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan
TSRO: 93.24 (-0.38)
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
GlobeNewswire - Mon Apr 04, 7:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company's Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
TSRO: 93.24 (-0.38)
TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042
GlobeNewswire - Tue Mar 29, 7:08AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced it has dosed the first patient in a Phase 1, dose-escalation study of its lead anti-PD-1 monoclonal antibody candidate, TSR-042. Following identification of a dose and schedule for TSR-042, the trial is planned to expand into tumor specific cohorts.
TSRO: 93.24 (-0.38)
TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement
GlobeNewswire - Tue Mar 29, 7:08AM CDT
-- Goal to identify novel small molecule therapeutics against undisclosed immuno-oncology targets
TSRO: 93.24 (-0.38)
TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
GlobeNewswire - Wed Mar 23, 8:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for oral rolapitant has been submitted to and validated by the European Medicines Agency. Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist that is marketed by TESARO in the United States under the brand name VARUBI(R).
TSRO: 93.24 (-0.38)
Ally Bridge Group (ABG) Completes Its Investment in TESARO, Inc. (TSRO)
PR Newswire - Mon Mar 21, 10:25AM CDT
Ally Bridge Group ("ABG"
, a global healthcare-focused investment group, announced that it has completed an equity investment in TESARO, Inc. (NASDAQ:TSRO), an oncology-focused, commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, USA. This investment was made as part of a private placement of 4.4 million shares of TSRO common stock that closed on March 17, 2016, resulting in gross proceeds of $155 million. TSRO: 93.24 (-0.38)
TESARO Announces Closing of $155 Million Private Placement
GlobeNewswire - Fri Mar 18, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 million shares of common stock at a price of $35.19 per share. This transaction resulted in total gross proceeds to the Company of approximately $155 million. TESARO intends to use the proceeds from the financing primarily to support the development of its product pipeline and for general corporate purposes.
TSRO: 93.24 (-0.38)
